Chinese Advanced-Manufacturing Buyers Acquiring Overseas Technology

A Chinese advanced-manufacturing group identifies an overseas technology company that owns specialist software, patents, production know-how and customer relationships. The buyer wants to sign quickly because a competing bidder is active. The investment team focuses on valuation, exclusivity and financing; the engineers focus on the technology roadmap. Only late in the process does someone ask whether the technology can lawfully be transferred to the Chinese buyer or its overseas subsidiary. That sequencing can destroy deal value.

China's outbound investment regime and export-control regime solve different legal problems. The National Development and Reform Commission's overseas-investment rules govern enterprise outbound investments, while MOFCOM's Overseas Investment Management Measures regulate overseas investment through filing and approval mechanisms.^[1][2] Separately, the Export Control Law regulates transfers of controlled goods, technologies and services and expressly includes related technical materials and data.^[3] The 2024 Regulations on Export Control of Dual-Use Items further operationalize dual-use controls.^[4] The narrow transaction issue is therefore not whether a Chinese company may buy an overseas target in the abstract. It is whether the buyer should become legally bound before it knows whether the target's technology can be transferred, accessed, integrated and used as assumed in the valuation model.

The specific problem#

Transaction architecture and China-side approvals#

Treat the acquisition and the technology transfer as separate legal workstreams. an overseas share acquisition can be legally permissible even when transfer of particular technology is restricted. That distinction should be built into the deal process from the first diligence request. The M&A workstream should identify the shares, assets, governance rights, financing and closing approvals. The technology-control workstream should identify what the buyer actually expects to receive: patents, source code, drawings, test data, production recipes, engineering services, software access, prototypes and continuing technical support. The Export Control Law's scope is broader than physical exports. Article 2 covers controlled items including goods, technologies and services and expressly includes technical materials and data related to controlled items.^[3] For a technology acquisition, this means the legal question may arise through data-room access, post-closing engineering collaboration or remote transfer of technical documentation, not only shipment of machinery.

A buyer should therefore create a "value-critical technology schedule" before agreeing price. For each item, the schedule should state the current owner, legal protection, location, access method, expected transferee, applicable export-control classification, contractual restriction and whether host-country approval is required. If the schedule shows that a critical technology cannot be transferred to China but can remain with a foreign subsidiary, the transaction may still work. But the valuation and integration plan need to reflect that operating model.

Complete China-side ODI analysis before making the closing timetable unconditional. the NDRC Administrative Measures for Enterprise Overseas Investment define outbound investment broadly and establish filing or approval requirements depending on the project and whether sensitive countries, regions or industries are involved.^[1] MOFCOM's Overseas Investment Management Measures similarly use filing and approval mechanisms and define overseas investment to include establishing or acquiring overseas non-financial enterprises or obtaining ownership, control, management or other interests.^[2] For an acquisition, counsel should map: The relevant items include Chinese investment entity, offshore acquisition vehicle, total project amount, equity and debt components, guarantees, target jurisdiction, sensitive-country or sensitive-industry issues, and intended signing and closing dates.

The key drafting point is that ODI procedure belongs in the closing conditions, not in a post-signing administrative checklist. If the buyer signs an SPA requiring payment within twenty business days but the project's China-side procedures cannot realistically be completed in that period, the buyer may create a contractual default risk before any host-country issue appears. A strong SPA should identify which governmental or internal approvals are conditions precedent, which are merely covenants and which party bears delay risk. The buyer should not promise an approval outcome that remains within regulatory discretion. Export-control diligence must begin with technical classification, not product names. engineering teams often describe technology commercially: "precision controller," "simulation software," "test platform." Export-control analysis normally requires much more detail.

The buyer needs to obtain technical parameters, performance thresholds, software functionality, encryption characteristics, intended use, end users and source-code access. The 2024 dual-use regulations establish the current operational framework for dual-use controls, and the control list and temporary-control mechanisms must be checked against the actual technology.^[4] The legal team should classify at least: 1. physical equipment included in the transaction;

1. embedded software;
2. standalone software;
3. technical data and drawings;
4. post-closing technical services;
5. prototypes and samples.

A target's statement that it has "never needed an export license" is not enough. The relevant transfer after closing may be different from the target's historical distribution model. For example, a European target may have legally supplied equipment to customers in several countries but never transferred source code or controlled production technology to a Chinese parent. The acquisition can create a new transfer scenario that must be assessed independently.

Technology classification and diligence access#

The data room itself can create a technology-access problem. technology diligence often starts before signing. Engineers want source code, detailed drawings, test data and product roadmaps to confirm value. That diligence access should be reviewed before disclosure. A clean-team structure can be useful where sensitive technology cannot be shared with the broader Chinese buyer team before approval. Access may be limited to external experts, specific overseas personnel or a segregated technical reviewer. The target should record what was disclosed and under what legal basis. This is not merely a confidentiality issue. A confidentiality agreement cannot authorize a transfer prohibited by export-control law. The SPA should also distinguish information available for diligence from information deliverable at closing. Some technology may require a license or regulatory approval only when control changes or when the buyer receives broader access.

A buyer that cannot conduct full technical diligence should adjust transaction protection. It may require a price holdback, deferred consideration, technology-delivery condition or termination right if post-signing review shows that critical rights cannot be transferred. Define the intended end user and end use before the license analysis. articles 13 to 16 of the Export Control Law make end user and end use central to licensing and post-license obligations.^[3] The buyer should therefore decide early who will actually receive and use the technology. Possible recipients include: The relevant items include the Chinese parent, an offshore acquisition vehicle, the target itself after change of control, another foreign subsidiary, a China R&D center, and a Chinese joint venture.

These are not legally interchangeable. If the commercial model assumes that the target continues developing technology overseas while the Chinese parent receives only reports or finished products, the export-control profile may differ from a model involving immediate transfer of source code to China. The acquisition agreement should reflect the approved structure. Do not write a blanket obligation requiring the seller to "deliver all technology to Buyer at Closing" if some technology can lawfully remain only with specified entities or in specified jurisdictions. Post-closing retransfer also matters. If the technology is licensed for use by the target, the buyer needs controls preventing an operating subsidiary from forwarding it to another group company without review. Make technology deliverability a value condition, not a generic covenant. representations and warranties are useful, but they do not solve an acquisition where the buyer cannot lawfully receive the asset that justifies the price. For value-critical technology, consider specific conditions such as:

The relevant items include completion of required export-control classifications, receipt of identified transfer licenses, confirmation that key technology may remain accessible after change of control, execution of replacement licenses where the target currently relies on third-party technology, and delivery of source-code escrow or controlled access where lawful. If a condition fails, the SPA should say what happens. Options include termination, price reduction, deferred closing of a business line, carve-out of restricted technology or use of an overseas ring-fenced subsidiary. A generic covenant to use "reasonable efforts" is insufficient where the buyer's investment thesis depends on a specific legal result. The purchase price allocation can also help. If 40% of the valuation is attributed to a technology platform that cannot be transferred as expected, the contract should provide a mechanism for repricing rather than forcing the buyer to litigate damages years later.

End-user design and transfer conditions#

Joint-venture and governance terms must protect controlled technology after closing. a Chinese buyer may acquire less than 100% or may keep foreign management after closing. The governance documents should address technology access as a reserved compliance matter. Board or management approval should be required for: The relevant items include transfer of controlled technology to affiliates, granting new user access, relocating R&D, subcontracting technical work, transferring production equipment, changing end use, and integrating repositories.

Information rights also need nuance. A shareholder may ordinarily expect broad access to company information, but that right should be implemented consistently with export-control restrictions. The buyer should avoid creating a governance contradiction in which the shareholder agreement promises unrestricted access while export-control rules prohibit the target from providing certain data to the shareholder's personnel. A practical solution is to define permitted information categories and create controlled access protocols for restricted data. Financing documents should not assume unrestricted technology integration. acquisition financing often contains assumptions about synergies, integration milestones and target cash flow. If the lender requires rapid integration of technology into China operations, export-control delay can become a financing default. The finance team should therefore map regulatory dependencies into the debt documents. Questions include:

The relevant items include Is drawdown conditional on technology transfer?, Does a failed export license constitute a material adverse effect?, Are acquisition debt covenants based on synergy targets?, and Can the buyer restructure the acquisition if certain technology remains offshore?. Lenders may also require sanctions and export-control representations. Those representations should be reviewed against the actual diligence rather than accepted as standard boilerplate. The buyer's board should receive a financing scenario showing the effect if technology integration is delayed six or twelve months. Case study: aerospace component acquisition. assume a Xi'an advanced-manufacturing group agrees to acquire a European aerospace component company. The target owns: The relevant items include patents for component design, proprietary simulation software, test equipment, production drawings, and customer certifications.

The buyer values the target partly because it plans to move simulation and testing capability to a China R&D center. During late diligence, external counsel identifies that some technical data and software may require host-country export authorization. The physical shares can be transferred, but the buyer may not receive the expected technology immediately. A poor SPA would require full payment at closing and contain only a general warranty that the target owns its IP. A stronger structure would: 1. identify the restricted technology precisely;

1. make relevant approvals a condition;
2. allow the target to retain technology offshore if necessary;
3. give the Chinese group controlled output access rather than unrestricted source access;
4. defer part of the price until the integration milestone is legally achieved;
5. permit termination or carve-out if the approval is denied.

The buyer then acquires a business model it can legally operate, not merely shares in a company whose value cannot be integrated.

Governance, financing and closing mechanics#

The investment committee should receive a regulatory critical path. before final approval, the investment paper should show a critical path linking: 1. target technical diligence;

1. ODI analysis;
2. host-country foreign-investment approvals;
3. export-control classification;
4. required technology licenses;
5. signing;
6. closing;
7. post-closing technology migration. Each item should identify owner, expected timing and whether failure blocks closing or only delays integration. This is more useful than separate legal memoranda that management must reconcile itself. The board should also see the downside case. If technology remains offshore permanently, can the target still generate the projected value? If not, the deal should not be priced as though unrestricted integration is certain. Preserve a transaction-specific compliance file after closing. export-control compliance does not end with the closing binder. The buyer should preserve: The relevant items include classification analysis, licenses, end-user and end-use documentation, technology-access logs, conditions imposed by regulators, internal approvals, and retransfer restrictions.

The target's IT and engineering systems should implement the legal restrictions operationally. If the license permits access only by specified entities, system permissions should reflect that rule. If retransfer requires approval, the group's normal repository-sharing process should not override it. The buyer needs to also conduct a post-closing review before major integration steps such as moving R&D, relocating equipment or granting China engineers repository access. Technology ownership diligence must distinguish legal title from transferability. an acquisition target may own patents while relying on software, data or know-how licensed from third parties. The buyer should not equate patent ownership with control of the complete technology stack. For each value-critical technology, diligence should identify: The relevant items include legal owner, inventor or developer, employee or contractor assignment, third-party license, sublicensing rights, change-of-control restrictions, territorial restrictions, export-control restrictions, and open-source dependencies.

A target can legally own its proprietary source code but still lack the right to transfer a third-party library or technical dataset to the Chinese buyer. Conversely, a target may use technology under an exclusive long-term license that is commercially sufficient even though it does not own the underlying patent. The SPA should therefore represent not merely that the target "owns or has rights to use" its technology. For key assets, the buyer should obtain a schedule stating the exact legal basis for continued use after closing. If a third-party license terminates on change of control, replacement consent belongs in the conditions precedent. If consent cannot be obtained before signing because the counterparty would learn of the deal, the buyer should negotiate a closing risk allocation rather than assume the problem can be solved later.

Technology ownership, personnel and partial closing#

Management retention and inventor mobility can be as important as formal IP rights. technology businesses often derive value from engineers who know how to operate, modify and commercialize the IP. A buyer should identify: The relevant items include key inventors, source-code maintainers, certification holders, customer-facing technical managers, and employees holding tacit manufacturing know-how. The employment and retention workstream should be integrated with the technology-transfer plan. If a license allows technology to remain in the target but all engineers leave at closing, the buyer may still lose the practical capability it expected to acquire. Retention arrangements should be reviewed under applicable local employment law and should not rely on unenforceable post-employment restrictions. Where employees will receive access to controlled technology after a change in ownership, export-control eligibility and information-access design may also need review. The board should therefore evaluate "technology deliverability" as a combination of legal rights, regulatory permissions and human capability. A closing should be capable of partial completion if only one technology stream is delayed. complex acquisitions do not always need to fail entirely because one regulatory permission remains outstanding. Where legally and commercially feasible, the SPA can separate:

The relevant items include share transfer, delivery of unrestricted IP, restricted technology access, deferred integration, and contingent consideration. For example, the buyer may close the acquisition while leaving a restricted R&D repository under controlled overseas management until a license is granted. Part of the purchase price can remain deferred or in escrow until the agreed technology milestone occurs. This structure is useful only if governance is carefully designed. The buyer must still receive enough control to protect the target's business while respecting restrictions on technical access. The seller should also have clear obligations to maintain the restricted technology, support applications and avoid transferring it elsewhere during the deferred period. A partial-closing architecture is far stronger than discovering after signing that the entire deal depends on one unallocated regulatory risk. The final diligence report should contain a technology-deliverability conclusion. most M&A reports contain sections titled corporate, IP, regulatory and employment. For a technology acquisition, management needs a cross-cutting conclusion. For each value-critical technology, the final report should answer:

1. Does the target own or lawfully control it?
2. Can the buyer's intended entity receive or access it?
3. Is any license or approval required?
4. Can key personnel continue supporting it?
5. What happens if transfer is delayed or denied?
6. Which SPA protection addresses the risk? This turns legal diligence into a transaction decision. A board should not approve the acquisition merely because every legal workstream has produced a memorandum. It should approve only after those memoranda have been reconciled into one operating model showing what the buyer will actually control after closing.

Board-level decision controls and post-closing compliance#

Host-country foreign investment review must be mapped separately from China-side approvals. technology acquisitions can trigger host-country foreign investment screening even where the target is not in a traditionally regulated sector. The buyer should therefore ask local counsel to identify whether the target's technology, government customers, infrastructure role or sensitive data creates a filing or approval requirement. This review should be reflected in the transaction timetable independently from China's ODI steps. If both China-side ODI and host-country screening are conditions, the SPA should identify which party controls each filing, what information must be shared and how regulatory remedies are handled. A host regulator may request restrictions on access, governance or data that materially affect the buyer's integration plan. The buyer needs to not agree in advance to accept any remedy necessary to obtain approval. The obligation should be calibrated to the economic assumptions underlying the deal.

The board should approve a downside operating model. before signing, management should show the board how the target will operate if the most valuable technology cannot be transferred to China for twelve months or permanently. The downside model should address: The relevant items include where R&D remains, who can access source code, whether Chinese engineers can receive outputs, how customer support continues, whether synergies are delayed, and what price protection applies.

If the transaction is still attractive under that model, the regulatory risk may be acceptable. If the investment thesis collapses without immediate technology migration, the SPA should make deliverability a true closing condition rather than a post-closing aspiration. Technology-integration warranties should be tested against the actual operating model. if the buyer expects the target to supply engineering support to China after closing, diligence should confirm that customer contracts, employment agreements and third-party licenses allow that support. The seller's IP warranty should not be treated as proof that every engineer can work on every China project. A transition plan should identify which technical services can begin immediately, which require approval and which must remain ring-fenced. That final operating review often reveals integration constraints that ordinary IP ownership diligence misses.

Conclusion#

For a Chinese advanced-manufacturing buyer, the central risk in an overseas technology acquisition is not simply whether the shares can be purchased. It is whether the buyer can lawfully receive and use the technology on which the valuation depends. China's ODI rules, the Export Control Law and the dual-use regulations operate through separate legal mechanisms.^[1][2][3][4] A well-structured transaction therefore treats investment approval, technology classification, end-use controls and transfer licensing as parallel critical paths. The practical rule is simple: do not sign an unconditional technology acquisition before the legal deliverability of the critical technology has been mapped into the SPA.

Legal and regulatory sources#

^[1] NDRC, Administrative Measures for Enterprise Overseas Investment (Order No. 11), effective March 1, 2018: https://zfxxgk.ndrc.gov.cn/web/iteminfo.jsp?id=18522 ^[2] MOFCOM, Overseas Investment Management Measures (MOFCOM Order No. 3 of 2014): https://www.mofcom.gov.cn/zcfb/blgg/art/2014/art_1d349047003649b7ba2cd5672c1debed.html ^[3] Export Control Law of the People's Republic of China, especially Articles 2 and 12-16: https://www.npc.gov.cn/englishnpc/c2759/c23934/202112/t20211209_384804.html ^[4] State Council, Regulations on Export Control of Dual-Use Items, effective December 1, 2024: https://exportcontrol.mofcom.gov.cn/article/zcfg/gnzcfg/gzjgfxwj/202410/1057.html

General legal information only; not legal advice for a specific transaction.